Getein Biotech, Inc (SHA:603387)

Market Cap	4.61B +14.6%
Revenue (ttm)	1.08B -1.1%
Net Income	232.66M +15.2%
EPS	0.46 +15.3%
Shares Out	507.15M
PE Ratio	20.66
Forward PE	n/a
Dividend	0.18 (1.93%)
Ex-Dividend Date	Sep 15, 2025

Volume	11,233,581
Average Volume	15,370,166
Open	9.33
Previous Close	9.34
Day's Range	9.08 - 9.49
52-Week Range	7.62 - 11.42
Beta	0.12
RSI	41.08
Earnings Date	Apr 30, 2026

About Getein Biotech

Getein Biotech, Inc researches, develops, produces, and sells in vitro diagnostic products in China and internationally. The company provides diagnostic reagents and analyzers; calibrators; reagent raw materials, such as monoclonal and polyclonal antibodies, antigen, antiserum, and microsphere; and cardiac marker, inflammation, renal function, coagulation, thyroid function, fertility, diabetes care, and thrombus products. It also offers products in the area of cardiovascular, inflammatory, diabetes, fertility, renal, liver, and others. The comp...

• Industry: Medical Devices
• Sector: Healthcare
• Founded: 2002
• Employees: 1,947
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 603387

Financial Performance

In 2025, Getein Biotech's revenue was 1.05 billion, a decrease of -9.71% compared to the previous year's 1.16 billion. Earnings were 220.66 million, a decrease of -1.33%.